Each template is built on a framework tested and refined through extensive industry experience
Clinical trials suggest that brand-name tirzepatide can produce slightly greater weight loss on average compared to semaglutide
Semaglutide belongs to a newer class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists
Compounded medications are different from FDA-approved generics but provide affordable access to the same active ingredient now rather than waiting 10-15 years
Before recommending semaglutide, tirzepatide, or another medically supervised weight-loss strategy, a physician may review weight history, prior weight-loss attempts, BMI, waist circumference, body composition goals, A1C, fasting glucose, insulin-resistance risk, cholesterol, triglycerides, blood pressure, liver enzymes, fatty liver risk, kidney function, current medications, diabetes medication use, history of pancreatitis, gallbladder disease, gastrointestinal symptoms, thyroid history, protein intake, exercise habits, sleep quality, hormonal symptoms, inflammation-related concerns, side-effect tolerance, and long-term maintenance planning
Supplementary information Supplementary Tables 18 Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
